Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10294622 | 0.81 | SORD (0.51) | SORDHRH3KDM4ELMNAL3MBTL1 | |
| SCHEMBL31140251 | 0.79 | HRH3 (0.55) | SORDHRH3KDM4EDRD2DRD3 | |
| SCHEMBL23374607 | 0.79 | HRH3 (0.55) | SORDHRH3KDM4EDRD2DRD3 | |
| SCHEMBL9558287 | 0.78 | SORD (0.51) | SORDHRH3KDM4ELMNAL3MBTL1 | |
| SCHEMBL19035675 | 0.76 | HRH3 (0.47) | SORDHRH3KDM4ELMNAL3MBTL1 | |
| SCHEMBL15887427 | 0.75 | SORD (0.51) | SORDHRH3KDM4ELMNAL3MBTL1 | |
| SCHEMBL2074813 | 0.75 | LMNA (0.54) | SORDHRH3KDM4ELMNAL3MBTL1 | |
| SCHEMBL3137995 | 0.75 | HRH3 (0.52) | SORDHRH3KDM4EDRD4DRD2 | |
| SCHEMBL4498037 | 0.75 | HRH3 (0.46) | SORDHRH3KDM4ELMNAL3MBTL1 | |
| SCHEMBL3145713 | 0.74 | SORD (0.48) | SORDHRH3KDM4ELMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131025-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | EGFR, ABL1, ERBB2 | SORD 4685/4885HRH3 801/4885KDM4E 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.